"All there is to investing is picking good stocks at good times and staying with them as long as they remain good companies", said Warren Buffet, reminding us that patience and discipline are key to successful investing. Stocks quietly climbing to new 52-week highs could be a sign that the market is recognizing consistent performance, strong fundamentals, or upcoming catalysts.The following are some of the stocks that hit new 52-week highs yesterday. Do you already own any of them? Are any on your watchlis ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ranks among the best biotech stocks to buy. UBS reaffirmed its Buy rating for BridgeBio Pharma, Inc. (NASDAQ:BBIO) on September 22, citing the company’s Attruby medication launch. The firm is optimistic about Attruby’s launch trajectory, citing a high number of new patient diagnoses. According to UBS, Attruby has the potential to become a major product that generates over $4 billion in long-term revenue, which is bolstered by growing data showing how it differs from r ...

Core Insights - BridgeBio Pharma, Inc. (NASDAQ:BBIO) is recognized as a promising biotech stock by hedge funds, with Piper Sandler analysts maintaining an 'Overweight' rating and a price target of $68, indicating a potential upside of nearly 33% [1] - The company's third-quarter performance is expected to mirror the second quarter in terms of free-drug distribution and gross-to-net adjustments, with the German launch of Beyonttra (Attruby) showing stronger results than the initial U.S. launch due to wide access at approval [2] - BridgeBio has demonstrated impressive financial performance, achieving one-year and three-year returns of 100.67% and 413.98%, respectively, significantly outperforming the market returns of 15.34% and 85.36% [3] Company Overview - BridgeBio Pharma, Inc. is a California-based commercial-stage biopharmaceutical company focused on developing transformative medicines for genetic diseases and cancers, founded in 2015, and offers products such as Attruby and low-dose infigratinib [4]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - BridgeBio Pharma's heart-disease drug, Attruby, has shown promising results in reducing the risk of death by nearly 50% in an exploratory study, which could significantly impact treatment approaches for cardiomyopathy [1][2][4] Group 1: Drug Efficacy and Approval - Attruby is approved for treating cardiomyopathy due to transthyretin amyloidosis, with a 49% lower risk of death observed in patients after 30 months of treatment [2][5] - The drug's effects were noticeable within just one month of treatment, suggesting the need for earlier diagnosis and intervention [3][7] - Attruby has been marketed since late 2024, generating $5.9 million in its first quarter, which increased to $71.5 million in subsequent quarters, with a forecast of $94.9 million for the current quarter [5][6] Group 2: Market Potential and Competition - Analysts predict Attruby could become a blockbuster drug by 2027, competing against Pfizer's Vyndaqel, which generated $5.45 billion in sales last year [5][6] - The difference in outcomes between Attruby and placebo was significant, with 53 events prevented per 100 treated patients after 30 months [8] Group 3: Clinical Implications - The cardiologist Dr. Ahmad Masri emphasizes that Attruby could shift the treatment paradigm for TTR-related cardiomyopathy, focusing on preventing serious cardiovascular events [9][10] - Continuous treatment with Attruby is highlighted as crucial for improving patient longevity and quality of life, as recovery from heart failure episodes can be challenging [10]

Core Insights - Acoramidis has shown significant early and sustained clinical efficacy in reducing cumulative cardiovascular outcomes in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) [1][2][3] Group 1: Clinical Efficacy - Acoramidis reduced cumulative cardiovascular mortality (CVM) or recurrent cardiovascular-related hospitalizations (CVH) by 49% through Month 30 compared to placebo, with a p-value of less than 0.0001 [1][3] - At Month 30, 53 events were avoided per 100 treated participants, with a 95% confidence interval of 29 to 79 [1][3] - Continuous treatment with acoramidis at Month 42 resulted in a 45% reduction in CVM compared to a switch from placebo to acoramidis, with a p-value of 0.0011 [3] Group 2: Patient Population Insights - Acoramidis demonstrated a consistent mitigation of NT-proBNP levels in patients with variant ATTR-CM, starting from Month 3 and continuing through Month 30 [3] - The findings highlight the importance of early and continuous treatment with acoramidis, regardless of TTR genotype, in both wild-type and variant ATTR-CM patients [3] Group 3: Regulatory Approvals - Acoramidis is approved as Attruby® by the U.S. FDA and as BEYONTTRA® by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency [4][5] Group 4: Future Developments - Additional data on the benefits of Attruby for ATTR-CM patients is planned for future medical meetings [4]

Core Insights - BridgeBio Pharma, Inc. is set to present significant findings related to its drug Acoramidis at the Heart Failure Society of America Annual Scientific Meeting 2025, highlighting its focus on genetic diseases [1][6]. Group 1: Clinical Presentations - A late-breaking clinical trial presentation will discuss the effect of Acoramidis on cardiovascular outcomes in patients with ATTR-CM, presented by Dr. Ahmad Masri on September 28 [2]. - An oral presentation will reveal that continuous treatment with Acoramidis significantly reduced the risk of all-cause mortality and cardiovascular-related hospitalization at month 42 for patients with transthyretin amyloidosis, presented by Dr. Lily Stern on September 27 [2]. Group 2: Poster Sessions - A poster session will present results showing that Acoramidis mitigates the rise in NT-proBNP levels compared to placebo in patients with variant transthyretin amyloid cardiomyopathy, presented by Dr. Nitasha Sarswat on September 27 [3]. - Another poster will discuss the effect of Acoramidis on cardiac conduction abnormalities in transthyretin amyloid cardiomyopathy, presented by Dr. Brett W. Sperry on September 27 [3]. - A poster will address state-level differences in the incidence of transthyretin amyloid cardiomyopathy among U.S. veterans after the introduction of disease-modifying therapy, presented by Dr. Sandesh Dev on September 28 [3]. Group 3: Product Information - Attruby™ (acoramidis) is indicated for treating cardiomyopathy associated with wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, aimed at reducing cardiovascular death and related hospitalizations [4]. Group 4: Safety Information - Adverse reactions reported for Attruby include diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo), with most being mild and resolving without discontinuation of the drug [5].

Core Viewpoint - Investors in BridgeBio Pharma Inc (BBIO) have new options available for May 2026 expiration, presenting potential opportunities for higher premiums in options trading due to the time value associated with the contracts [1] Options Analysis - The put contract at the $52.50 strike price has a current bid of $6.50, allowing investors to purchase the stock at an effective cost basis of $46.00 if sold [2] - The $52.50 strike represents a 1% discount to the current trading price, with a 63% chance of expiring worthless, potentially yielding a 12.38% return on cash commitment or 18.99% annualized [3] - The call contract at the $57.50 strike price has a current bid of $6.70, offering a total return of 20.74% if the stock is called away at expiration [4] - The $57.50 strike represents an 8% premium to the current trading price, with a 45% chance of expiring worthless, which could yield a 12.60% boost in returns or 19.33% annualized [7] Volatility Insights - The implied volatility for both the put and call contracts is approximately 57%, while the actual trailing twelve-month volatility is calculated at 52% [8]

Core Viewpoint - Analysts project a 10.55% upside for the Schwab 1000 Index ETF (SCHK) based on the average target prices of its underlying holdings, indicating potential growth in the ETF's value [1][2]. Summary by Category ETF Performance - The Schwab 1000 Index ETF (SCHK) is currently trading at $31.75 per unit, with an implied analyst target price of $35.10 per unit, suggesting a potential upside of 10.55% [2][3]. Underlying Holdings - Notable underlying holdings with significant upside potential include: - QXO Inc (Symbol: QXO) with a recent price of $20.77 and an average analyst target of $33.73, representing a 62.38% upside [2][3]. - SPS Commerce, Inc. (Symbol: SPSC) trading at $105.53, with a target price of $157.54, indicating a 49.29% upside [2][3]. - BridgeBio Pharma Inc (Symbol: BBIO) at a recent price of $51.21, with a target of $64.67, showing a 26.28% upside [2][3]. Analyst Target Justification - Questions arise regarding whether analysts' targets are justified or overly optimistic, considering recent company and industry developments. A high target relative to current trading prices may reflect optimism but could also lead to potential downgrades if targets are outdated [3].

Core Viewpoint - BridgeBio Pharma is competing with Pfizer and Alnylam Pharmaceuticals in the heart disease treatment market, claiming its drug is more effective and cost-efficient while accusing competitors of using "controversial strategies" [1][2]. Group 1: Competition Overview - The competition centers around the treatment of ATTR cardiomyopathy, which has significant market potential, attracting both large pharmaceutical companies and innovative startups [2]. - Pfizer's drug Vyndamax, approved in 2019, is projected to generate approximately $6.6 billion in revenue this year [2]. - BridgeBio's drug Attruby is expected to surpass $300 million in sales this year, with projections of reaching $2.1 billion by 2030 [3]. Group 2: Claims and Counterclaims - BridgeBio's CEO Neil Kumar criticized Pfizer's presentation of data as unfair, comparing it to contrasting the best performance of one runner with the worst of another [1][2]. - Pfizer responded to accusations regarding misleading information, claiming the video in question was a "misplay" and asserting that their data presentation is accurate [2][3]. Group 3: Regulatory and Market Dynamics - The FDA's Office of Prescription Drug Promotion (OPDP) oversees drug advertising, but it often only becomes aware of issues through complaints from competitors or doctors [5]. - There are concerns about OPDP's capacity to handle complaints due to significant staff reductions earlier this year [5]. Group 4: Research and Data Presentation - Kumar expressed dissatisfaction with a study published in the New England Journal of Medicine regarding Alnylam's drug Amvuttra, arguing that the data presented was adjusted in a misleading way [6]. - Alnylam's research head defended the adjustments made to the data, stating they were intended to clarify drug efficacy [7].